any of these below I would love to ask 1.Given the share price...

any of these below I would love to ask

1.Given the share price is down over 90%, what would you say to long-term shareholders who feel their trust — and capital — have been diluted more than the actual shares?

2.How many more 'exciting developments' are planned before we see material progress in patient recruitment or trial results?

3.At what point does ‘extended recruitment’ stop being a timeline issue and start being a business model?

4.Can you clarify the company’s current burn rate and runway? At this rate, how many quarters until the next inevitable capital raise?

5.Is the leadership team actively buying shares on-market, or are we only enthusiastic when it comes to issuing options?

6.Why have multiple pipeline assets remained in early-stage or recruiting limbo for so long? Is this by design, or just unfortunate reality?

7.How do you define success at Imugene — scientific progress, commercialisation, or raising capital effectively?

8.If we had $1 for every time 'we're very excited' was said on a webinar, would we still need another capital raise?

9.Can we expect any trials to reach the completion stage before the next Olympics?

10.On a day when the ASX is up over 300 points and we close flat… what message do you think that sends about investor confidence?